Stopped: Could not secure additional funding to continue the study. Pilot phase of study completed.
The prospective pilot study will address the critical need for more precise characterizations of the acute visual effects of the drug psilocybin by measuring the impact of acute psilocybin intoxication on a perceptual task known as visual surround suppression, compared to an active placebo control.
Age range
25 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Psychophysical Descrimination Threshold - No Surround Suppression (NS) Dose 1
Timeframe: 3 hours after dose 1
Psychophysical Descrimination Threshold - No Surround Suppression (NS) Dose 2
Timeframe: 3 hours after dose 2
Psychophysical Descrimination Threshold - Orthogonal Surround Suppression (OS) Dose 1
Timeframe: 3 hours after dose 1
Psychophysical Descrimination Threshold - Orthogonal Surround Suppression (OS) Dose 2
Timeframe: 3 hours after dose 2
Psychophysical Descrimination Threshold - Parallel Surround Suppression (PS) Dose 1
Timeframe: 3 hours after dose 1
Psychophysical Descrimination Threshold - Parallel Surround Suppression (PS) Dose 2
Timeframe: 3 hours after dose 2